Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Original Article

J. Cortes, H.S. Rugo, D.W. Cescon, S.-A. Im, M.M. Yusof, C. Gallardo, O. Lipatov, C.H. Barrios, J. Perez-Garcia, H. Iwata, N. Masuda, M.T. Otero, E. Gokmen, S. Loi, Z. Guo, X. Zhou, V. Karantza, W. Pan, and P. Schmid

N Engl J Med 2022;387:217-226

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
07/20/2022
Course expires: 
07/21/2024

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation